Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty

Cornea. 2008 Apr;27(3):314-9. doi: 10.1097/ICO.0b013e3181608561.

Abstract

Purpose: To compare the corneal and aqueous penetration and pharmacokinetics of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions and their effect on corneal reepithelialization after penetrating keratoplasty.

Methods: In this randomized, open-label, parallel-controlled study, corneal and aqueous penetration and the pharmacokinetic parameters of topically applied gatifloxacin 0.3% and moxifloxacin 0.5% (2 preoperative doses of 1 drop given 5 minutes apart) were estimated by using a sparse sampling method. Corneal and aqueous samples were collected 0.25, 0.5, 1, or 2 hours after the final dose. The concentration was determined by a high-performance liquid chromatography method. Stromal Cmax:MBC50 (maximum drug concentration in serum to 50% minimum bactericidal concentration) ratios for selected ocular pathogens were also assessed. Postoperative corneal reepithelialization at days 1, 3, and 7 was evaluated and compared between groups.

Results: The calculated pharmacokinetic parameters were higher with moxifloxacin 0.5% than with gatifloxacin 0.3%. The stromal Cmax was 48.5 versus 15.7 microg/g (P = 0.04), and the stromal AUC0-2 (area under the concentration-time curve from 0 to 2 hours) was 30.9 versus 13.6 mug.h/g (P < 0.05). The endothelial Cmax was 76.1 versus 7.3 microg/g (P > 0.05), and the endothelial AUC0-2 was 43.9 versus 9.8 microg.h/g (P < 0.05). The aqueous Cmax was 0.9 versus 0.3 microg/mL (P > 0.05), and the aqueous AUC0-2 was 1.2 versus 0.4 microg.h/mL (P < 0.05). Stromal Cmax:MBC50 ratios were higher in the moxifloxacin 0.5% group for each pathogen tested. The corneal reepithelialization rates were comparable between groups.

Conclusions: Topical preoperative moxifloxacin 0.5% achieved greater corneal and aqueous penetration than did gatifloxacin 0.3%. The clinical significance of this difference is not known. Postoperative use of these agents had similar effects on corneal reepithelialization.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / pharmacokinetics*
  • Aqueous Humor / metabolism*
  • Aza Compounds / administration & dosage
  • Aza Compounds / pharmacokinetics*
  • Biological Availability
  • Chromatography, High Pressure Liquid
  • Cornea / metabolism*
  • Female
  • Fluoroquinolones / administration & dosage
  • Fluoroquinolones / pharmacokinetics*
  • Gatifloxacin
  • Humans
  • Keratoplasty, Penetrating*
  • Male
  • Middle Aged
  • Moxifloxacin
  • Ophthalmic Solutions / administration & dosage
  • Ophthalmic Solutions / pharmacokinetics*
  • Quinolines / administration & dosage
  • Quinolines / pharmacokinetics*
  • Tissue Distribution
  • Wound Healing

Substances

  • Anti-Infective Agents
  • Aza Compounds
  • Fluoroquinolones
  • Ophthalmic Solutions
  • Quinolines
  • Gatifloxacin
  • Moxifloxacin